Nasdaq:ORIC

ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 20:00 ET  | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…

13 minutes ago

ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 01:00 ET  | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…

20 hours ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025 16:30 ET  | Source: ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE…

6 months ago